Replimune Group (7R8) Stock Overview

A clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. More details

7R8 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 91% below our estimate of its fair value

Revenue is forecast to grow 47.12% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the German market

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

7R8 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW433,395 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

433,395 investors already sharing narratives

View all narratives

Replimune Group, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Replimune Group
Historical stock prices
Current Share Price	US$11.15
52 Week High	US$13.83
52 Week Low	US$1.43
Beta	0.94
1 Month Change	-4.82%
3 Month Change	20.00%
1 Year Change	316.04%
3 Year Change	-28.06%
5 Year Change	-59.01%
Change since IPO	-8.68%

Recent updates

Shareholder Returns

	7R8	DE Biotechs	DE Market
7D	2.4%	4.9%	0.3%
1Y	316.0%	0.8%	5.0%

Return vs Industry: 7R8 exceeded the German Biotechs industry which returned -0.5% over the past year.

Return vs Market: 7R8 exceeded the German Market which returned 4% over the past year.

Price Volatility

Is 7R8's price volatile compared to industry and market?
7R8 volatility
7R8 Average Weekly Movement	35.8%
Biotechs Industry Average Movement	5.4%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	12.4%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 7R8's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 7R8's weekly volatility has increased from 30% to 36% over the past year.

About the Company

Founded	Employees	CEO	Website
2015	465	Sush Patel	www.replimune.com

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.

Replimune Group, Inc. Fundamentals Summary

How do Replimune Group's earnings and revenue compare to its market cap?
7R8 fundamental statistics
Market cap	€1.07b
Earnings (TTM)	-€259.03m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.1x

P/E Ratio

Is 7R8 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7R8 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$297.01m
Earnings	-US$297.01m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-3.15
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	79.6%

How did 7R8 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/21 12:49
End of Day Share Price	2026/09/21 00:00
Earnings	2026/06/30
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Replimune Group, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Clarence Powell	BMO Capital Markets Equity Research
Evan Seigerman	BMO Capital Markets Equity Research
Guyn Kim	BMO Capital Markets Equity Research

Replimune Group (7R8) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Replimune Group, Inc. Competitors

Hamlet BioPharma

Biotest GmbH KGaA

Biotest

Formycon

Price History & Performance

Recent News & Updates

New minor risk - Profitability

Replimune Group, Inc. Announces Appointment of Michelle Dinapoli to Chief Commercial Officer, Effective August 18, 2026

CEO & Director recently sold €442k worth of stock

New minor risk - Shareholder dilution

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $149.999956 million.

Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action

Recent updates

New minor risk - Profitability

Replimune Group, Inc. Announces Appointment of Michelle Dinapoli to Chief Commercial Officer, Effective August 18, 2026

CEO & Director recently sold €442k worth of stock

New minor risk - Shareholder dilution

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $149.999956 million.

Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action

Replimune Announces Favorable Outcome of FDA Advisory Committee Meeting for RP1 in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 15, 2026

Replimune Group, Inc. Announces U.S. Food and Drug Administration Acceptance Of RP1 Biologics License Application Resubmission For Advanced Melanoma

Now 21% overvalued after recent price rise

Replimune Group Presents Three-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial of RP1 Plus Nivolumab in Patients with Anti-PD-1-Failed Melanoma

Replimune Group Announces Planned RP1 BLA Resubmission Following Discussion With FDA

Now 22% undervalued after recent price drop

Replimune Group, Inc. Receives Complete Response Letter From FDA For RP1 Biologics License Application For Treatment Of Advanced Melanoma

Replimune Group, Inc. Presents Late-Breaking Abstract and Additional Posters on Rp1 At 40Th Annual Meeting of the Society for the Immunotherapy of Cancer (Sitc 2025)

Replimune Group, Inc. Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 10, 2026

Replimune Group, Inc. Highlights Acral Melanoma Data for Rp1 Plus Nivolumab At the ESMO Congress 2025

Replimune Provides Update Following Type A Meeting with FDA

Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman

Replimune Group, Inc., Annual General Meeting, Sep 03, 2025

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc

Replimune Group, Inc. Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Replimune Group, Inc. Presents New Analyses from the Ignyte Study of Rp1 Plus Nivolumab in Anti-Pd-1 Failure Melanoma At the 2025 American Society of Clinical Oncology Annual Meeting

Replimune Group, Inc. to Report Q4, 2025 Results on May 22, 2025

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

Replimune Group, Inc. Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

No longer forecast to breakeven

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

CEO & Director recently sold €298k worth of stock

No longer forecast to breakeven

Insufficient new directors

Replimune Group, Inc. Announces Executive Appointments

Now 23% undervalued

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold €150k worth of stock

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors